Cargando…
Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
Targeting tumor-associated blood vessels to increase immune infiltration may enhance treatment effectiveness, yet limited data exist regarding anti-angiogenesis effects on the tumor microenvironment (TME). We hypothesized that dual targeting of angiogenesis with immune checkpoints would improve both...
Autores principales: | Tran, Thuy T., Caulfield, Jasmine, Zhang, Lin, Schoenfeld, David, Djureinovic, Dijana, Chiang, Veronica L., Oria, Victor, Weiss, Sarah A., Olino, Kelly, Jilaveanu, Lucia B., Kluger, Harriet M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132152/ https://www.ncbi.nlm.nih.gov/pubmed/36821392 http://dx.doi.org/10.1172/jci.insight.157347 |
Ejemplares similares
-
Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023) -
A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023) -
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
por: Djureinovic, Dijana, et al.
Publicado: (2023) -
Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021) -
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)